100 Migraine drugs, A to Z: amiloride

May 12, 2018

Only about 20% of migraine sufferers experience an aura. The most common type of aura is visual and it typically consists of partial obscuration of vision with colorful zigzags and blind spots spreading over half of the visual field of both eyes. Sometimes, the aura consists of gradual narrowing of the visual fields which ends in tunnel vision or complete loss of vision. The typical duration is 20 to 60 minutes and usually the aura itself is not disabling, but the headache that follows can be more severe than during attacks without aura. Migraine aura can occur without a subsequent headache. In some people aura does interfere with normal functioning and can be more disabling than the headache. In rare instances, the visual disturbance persists for days, weeks, and months.

In such cases I do a battery of blood tests, including for RBC magnesium, vitamin B12, homocysteine, CoQ10 levels, and other. If RBC magnesium level is low or at the bottom of normal range, a gram of magnesium sulfate given intravenously can abort the aura. We sometimes give an infusion of magnesium without first doing a blood test.

Amiloride (Midamore) is a potassium-sparing diuretic (water pill), which means that unlike most diuretics, it does not deplete potassium. It is used to treat high blood pressure, heart failure and to remove excess fluid in the body. It has been reported to reduce aura and headache symptoms in 4 of 7 patients with otherwise intractable aura. Potential side effects of amiloride include dizziness, nausea, stomach pain, and diarrhea.

Other diuretics, such as acetazolamide, which is also used for barometric pressure-induced migraines and furosemide have also been reported to stop a prolonged visual aura. Other approaches to treat a persistent aura include the use of preventive migraine medications, such as a blood pressure medication, verapamil (Calan) or one of the epilepsy drugs, such as topiramate (Topamax), divalproex sodium (Depakote), or lamotrigine (Lamictal). An infusion of divalproex sodium derivative, valproic acid (Depakene) can be also tried.

Written by
Alexander Mauskop, MD
Continue reading
May 21, 2026
Research
Your Brain Has Many Pathways, And TMS Can Now Use Them
A groundbreaking University of Iowa study shows that personalized fMRI-guided TMS can now reach and modulate the deep hippocampus — the brain’s command center for memory, emotion, and migraine — without surgery or heavy medications. By mapping each patient’s unique neural pathways, TMS delivers precise stimulation to surface “control points” that influence deep brain structures. Generic approaches barely work, but individualized targeting produces clear, measurable changes. At our headache clinic, we combine TMS and fMRI to offer this advanced, personalized treatment for migraines, depression, PTSD, anxiety, and more.
Read article
May 10, 2026
Research
Elismetrep: A Promising New Experimental Migraine Treatment
Elismetrep is a promising experimental migraine medication that targets the TRPM8 pathway rather than serotonin or CGRP. Early clinical trials suggest it may offer a new option for patients who do not respond well to current treatments.
Read article
May 6, 2026
Alternative Therapies
New Research on Brain Excitability and TMS Treatment for Migraine
New research shows how the brain dynamically regulates excitability in real time—and why this matters for transcranial magnetic stimulation (TMS) as a treatment for migraine.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe